Navigation Links
Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
Date:11/14/2011

tion of heart failure hospitalization events.  Mesoblast expects that these outcomes will be central to the primary endpoint of a Revascor™ Phase 3 trial for product regulatory approval by the United States Food and Drug Administration (FDA).

The randomized, placebo-controlled 60-patient Phase 2 trial compared the safety and efficacy of three doses of Revascor™ on top of maximal approved therapies versus maximal therapies alone in patients with moderate-to-severe congestive heart failure (CHF) defined by New York Heart Association (NYHA) class II or III status and ejection fraction below 40%.  The trial enrolled both ischemic and non-ischemic heart failure patients.  Heart failure patients with this degree of severity are known to have a high cardiac mortality over a 12-24 month period despite being on maximal approved drug and device therapies.

Treatment with MPCs was well-tolerated, with 13% of patients developing transient or persistent anti-donor antibodies which were without clinical consequence. Over a 22-month mean follow-up period, only 1/45 (2%) patients who received a single injection of Revascor™ died of cardiac causes compared with 3/15 (20%) controls (p=0.02).  In addition, MPC treatment significantly delayed the time to a first Major Adverse Cardiac Event, MACE, a composite of cardiac death, heart attack or revascularization procedures (p=0.036), and reduced the overall risk for MACE by 78% (p=0.011).

Over a mean follow-up of 18 months, 0/15 patients who received the highest dose of MPC (150M) had been hospitalized for heart failure or had died.  In contrast, 3/15 (20%) controls and 6/30 (20%) patients who received low (25M) or mid (75M) doses of MPC had either been hospitalized with heart failure or had died. This clinical improvement associated with the 150M dose was accompanied by evidence of cardiac remodelling (reduction in left ventricular end systolic volumes compared with controls
'/>"/>

SOURCE Mesoblast
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
2. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
5. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
10. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
11. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... KENNEWICK, Wash. , Dec. 23, 2014 /PRNewswire/ ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that it has ... the Food and Drug Administration ("FDA") for marketing ... to Section 513(f)(2) of the U.S. Food, Drug ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... 2011 ArjoHuntleigh, Inc. is pleased to announce ... Compression Devices with HealthTrust Purchasing Group, L.P. (HealthTrust). ... members to take advantage of special pricing and ... (IPC) devices for the prevention of deep vein ...
... Ltd, a leading source for life science sector analysis and ... sales, revealed today that Sanofi is expected to take the ... hold it through 2016. The French drug maker has raced ... activity, with the $20bn purchase this year of US biotechnology ...
Cached Medicine Technology:ArjoHuntleigh Awarded Vascular Compression Contract With HealthTrust Purchasing Group 2Sanofi Tops Pfizer as Number One for Global Pharma Sales 2
(Date:12/26/2014)... AZ (PRWEB) December 26, 2014 ... source for the best in heating, cooling and ... for 24 hour emergency services in 2014 with ... alike know that Arizona is known for its ... company that understands the intricacies and details of ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, LunaDress.co.uk has updated ... dresses and related accessories. Now, all of the models at LunaDress.co.uk ... moment a groom lifts the wedding veil can turn out to ... stunning charm. A wedding veil can always bring surprise to a ... suggestions on how to choose veils for a big day ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... HOLX ) today announced that Patrick Sullivan, Executive ... at the Lehman,Brothers Eleventh Annual Global Healthcare Conference being ... Miami, Florida., Interested parties are invited to listen ... Thursday, March 20, at 10:15 a.m.,Eastern Time on the ...
... German . , Scientists at the ... of haemo-globin. Haemoglobin transports oxygen in the red blood ... new haemoglobin type appears optically to be transporting little ... a similar picture to patients suffering from an inherited ...
... ENGLEWOOD, Colo., March 17 Baxa Corporation ... Training, Academics and Resources),Center course offerings. Safe ... developed for nurses, pharmacists and physicians that ... course combines hands-on,experience with regulatory compliance and ...
... to new drugs to check vascular proliferation that is ... (HealthDay News) -- Researchers have pinpointed a biological pathway ... behind most cases of blindness in the United States. ... suggests a new therapeutic target for such ophthalmic diseases ...
... CARMEL, Ind., March 17 Conseco, Inc. (NYSE:,CNO) today ... Partners II,L.P. to nominate two of its representatives to ... been reviewing strategic,alternatives and has engaged the investment banking ... CEO Jim Prieur said, "We share with Steel Partners, ...
... Inc.,(Nasdaq: ANSS ), a global innovator of ... processes, today announced it is a,sponsor of the ... Museum of,Natural History in Pittsburgh. This is the ... accurate, immersive environments that are,composed of original fossil ...
Cached Medicine News:Health News:Hologic to Present at Lehman Brothers Healthcare Conference 2Health News:Bonn scientists discover new hemoglobin type 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 3Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 2Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 3Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 2Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 3
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers indicate the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Medicine Products: